Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

Cancer

Related Content

AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data

Feb 21 2022

AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

May 05 2022

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Genentech, Inc.

Additional Topics

Clinical Trials Research & Development ASCO Cancer BioPharmaceutical

More from ASCO

More from Conferences

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window